January 12, 2021
Weil advised Eli Lilly and Company in its $1 billion acquisition of Prevail Therapeutics Inc., a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The transaction closed on January 12, 2021.
The Weil team that advised Eli Lilly was led by Mergers & Acquisitions partner Raymond Gietz and included Mergers & Acquisitions partner Matthew Gilroy and Mergers & Acquisitions associate Tom Tsatsis. The team also included Technology & IP Transactions partner Jeffrey Osterman; Technology & IP Transactions/Privacy associate Kane Wishart; Executive Compensation & Benefits partner Amy Rubin; Tax partner Helyn Goldstein; and Tax counsel Eric Behl-Remijan.